PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Otava Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Otava Lead Like Library for Drug Discovery - The preclinical drug-discovery process requires the screening of millions of small organic molecules to find a suitable lead compound for one ultimately successful outcome - OtavaChemicals.com
Otava Lead Like Library for Drug Discovery

 

NewswireToday - /newswire/ - Kyiv, Kyivska, Ukraine, 2011/06/06 - The preclinical drug-discovery process requires the screening of millions of small organic molecules to find a suitable lead compound for one ultimately successful outcome - OtavaChemicals.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The preclinical drug-discovery process requires the screening of millions of small organic molecules to find a suitable lead compound for one ultimately successful outcome. A lead compound in drug discovery is a substance that displays pharmacological and/or biological activity and whose chemical structure is used as a starting point for chemical modifications in order to improve potency, selectivity or pharmacokinetic parameters.

Based on current data, effective lead compounds have lower molecular complexity when compared with drugs. They also have a smaller number of rings and rotatable bonds, lower molecular weight and they are more polar. The concept of leadlikeness is already having a significant impact on the design of chemical libraries.

Lead-like library, which is available from OTAVA Ltd. (otavachemicals.com), is a universal screening library containing about 57,000 compounds. This library is an integral part of the OTAVA chemical libraries and it can be used for high-throughput screening in addition to OTAVA's Drug-like Green Collection and Fragment Library. Comparing to Drug-like Green Collection, this Lead-like library has lower molecular weights (MW 160-400), smaller number of rotatable bonds (¡Ü 8) and number of hydrogen bond donors (¡Ü 4) and acceptors (¡Ü 8). It is done to extend potential chemical space for further lead optimization.

Any biologically unstable compounds and compounds comprising any reactive groups or atoms different to O, N, C, H, Br, I, Cl, F, or S were removed from the library.

This Lead-like library from OTAVA is of great help for medicinal chemists in achieving positive drug discovery outcome in a timely and cost-effective manner.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Otava Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Otava Lead Like Library for Drug Discovery

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Andrey Dmytrenko - OtavaChemicals.com 
+380 44 5222458 info[.]otavachemicals.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Otava Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Otava Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)